Edwards Lifesciences Corporation EW
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -75.77% | -73.78% | -74.28% | -67.11% | 181.58% |
| Total Depreciation and Amortization | 8.95% | 4.89% | 0.84% | 4.89% | 0.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 113.16% | 108.05% | 105.29% | 100.89% | -6,744.75% |
| Change in Net Operating Assets | 298.13% | -349.05% | 168.84% | -4,281.30% | 93.22% |
| Cash from Operations | 116.42% | 55.06% | 194.15% | 26.09% | -8.22% |
| Capital Expenditure | -38.50% | -10.70% | -3.09% | 26.92% | 29.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 96.83% | 96.69% | -- | 58.44% | -2,408.26% |
| Divestitures | -99.46% | -99.46% | -99.46% | 0.00% | -- |
| Other Investing Activities | 86.05% | 85.07% | 88.29% | -29,557.24% | -943.28% |
| Cash from Investing | -144.75% | -138.16% | -130.82% | -137.58% | 600.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11.46% | 15.42% | -3.01% | -7.44% | -7.30% |
| Repurchase of Common Stock | 12.23% | 24.61% | 22.94% | 46.95% | -68.38% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,736.90% | -10,650.00% | -7,561.29% | -19,425.00% | -237.70% |
| Cash from Financing | -4.30% | 11.72% | 2.67% | 35.65% | -95.03% |
| Foreign Exchange rate Adjustments | 130.33% | -268.75% | -216.06% | 117.09% | -206.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -123.30% | -136.53% | -106.24% | -143.56% | 167.26% |